

REMARKS


Claims 1-31 were originally filed in this application. In response to a Restriction Requirement dated May 31, 2001, Applicant elected Group V, corresponding to claims 1-13 and 23-31. Claims 2 and 14-22 were canceled in the Response filed on January 23, 2002. Claims 32 and 33 were added in the Amendment and Response, mailed October 1, 2002, to the Office Action dated May 1, 2002. Claim 8 was canceled in the response mailed January 30, 2003. A request for continued examination was filed on March 10, 2003 and new claim 34 was added. Claims 3-6, 8, 11, and 32-33 were canceled in the amendment submitted on August 30, 2004. Thus, claims 1, 7, 9, 10, 12, 13, 23-31 and 34 were pending at the time of the present Office action.

The present amendment is filed in response to the Office action mailed November 15, 2004. Without conceding the grounds for rejection and to expedite the prosecution of this case, the present amendment amends claims 1, 30, and 31 to relate to lung metastases and a dose of 50 mg/kg to 100 mg/kg of WR-2721. Support for the amendments may be found at least on page 13, lines 19-29 and page 20, lines 10-24. Claim 34 is canceled without prejudice or disclaimer herein. Thus, claims 1, 7, 9-10, 12, 13, and 23-31 are currently pending and are in condition for allowance. Applicant respectfully request allowance of the pending claims.

25513843.1

Also, Applicant reserves the right to pursue any previously presented claim or canceled claim in a continuation application. The Examiner is invited to contact the undersigned attorney at 713-651-5391 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Charles P. Landrum

Reg. No. 46,855

FULBRIGHT & JAWORSKI L.L.P.

600 Congress Avenue, Suite 2400

Austin, Texas 78701

713-651-5391

Date: March 15, 2005

25513843.1